
This cochrane meta-analysis from 2005 summarized twenty studies on the use of cardioselective betablockers in COPD. Note the attention to look at beta1 or cardioselective betablockers that have less effects on the bronchial beta 2 receptors. The authors concluded that : "Cardioselective beta-blockers, given to patients with COPD in the identified studies did not produce adverse respiratory effects. Given their demonstrated benefit in conditions such as heart failure, coronary artery disease and hypertension, cardioselective beta-blockers should not be routinely withheld from patients with COPD."
For a more recent look at the interplay between COPD and Heart Failure treatment check out this review in JACC.
No comments:
Post a Comment